BIOALVO is a biopharmaceutical company that specializes in research that lead to drug discovery process and in its early preclinical phase. The company's new and effective drug development programmes aim at combating severe Central Nervous System (CNS) and other neurodegenerative disorders, which market represents one of the fastest growing and the second largest therapeutic segment of the pharmaceutical industry. BIOALVO mission is to contribute to the development of better and more efficient drugs for human diseases, improving its society well being and quality of life.